comparemela.com
Latest Breaking News On - Combo strategy - Page 1 : comparemela.com
Polaris Group Initiates Phase 3 Trial: First Patient Successfully Dosed with ADI-PEG 20/Placebo plus Gemcitabine and Docetaxel for Difficult-to-Treat Leiomyosarcoma (LMS) -December 04, 2023 at 07:02 am EST
TAIPEI, Taiwan and SAN DIEGO, Dec. 04, 2023 Polaris Group , today announced that the first patient is successfully dosed in a pivotal Phase 3 trial that combines ADI-PEG 20 or placebo with.
Taipei
T-ai-pei
Taiwan
Gina-lee
Washington-university-in-st
Sarcoma-program
Polaris-group
Combo-strategy
Side-effects
Brian-van-tine
Lead-investigator
Director-developmental-therapeutics
vimarsana © 2020. All Rights Reserved.